An interventional study of CT angiography, FFR-CT and stress CT myocardial perfusion in Coronary Artery Disease, Chest Syndrome and Acute Myocardial Infarction, sponsored by Copenhagen University Hospital, Rigshospitalet. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Copenhagen University Hospital, Rigshospitalet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Coronary Artery Disease with a site in Denmark — 23 open to participants now, 44 under way, 5 of them phase 3. Coronary Artery Disease · Denmark.
Among the 184 studies in Coronary Artery Disease with a site in Denmark, this one is the 36th largest by planned enrollment of the 136 interventional ones that give a count, is one of 7 that started in 2021, is one of 88 with no phase, reaches primary completion later than 22 of the 43 other live ones, and was the 145th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →23 of the 184 studies in Coronary Artery Disease with a site in Denmark are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Denmark, United States, France and 1 more country
Ages 12–130
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
Odense University Hospital · Sites in Denmark
Ages 18+
Tina Vilsbøll · Sites in Denmark
Ages 18+
CSL Behring · Sites in Denmark, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 23 · Phase 4 15
First in 2002; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 455 across the 136 interventional studies, 329 across the 47 observational. Of the 116 that completed or were terminated, 27 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 184 have an industry lead sponsor. The 10 most frequent:
Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.
Copenhagen University Hospital, Rigshospitalet has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Coronary Artery Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02973529Aarhus University Hospital SkejbyThe Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study | 2026-11 |
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT06606821Tina VilsbøllThe Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | 2027-03-20 |
| NCT06944509Philips Clinical & Medical Affairs GlobalRADIQAL Study (Radiation Dose and Image Quality Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 184 studies in Coronary Artery Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.
Trial design
The DYNAMITE trial is an investigator-initiated, randomised controlled, open-labelled trial conducted in the Capital Region of Copenhagen, Denmark
The following hypothesis will be tested:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Status of coronary revascularization
Without previous coronary revascularization
Age>50 - \<65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy
Diagnostic Test: CT angiography, FFR-CT and stress CT myocardial perfusion
Evaluation and treatment strategy according to contemporary clinical practice
The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures.
Major Adverse Cardiovascular Events
cardiovascular death, acute myocardial infarction, stroke or hospitalization for heart failure
Time frame: 3 years
Individual components of the primary endpoint
cardiovascular death; acute myocardial infarction; stroke or hospitalization for heart failure
Time frame: 3 years
Acute myocardial infarction stratified by subtype
Subtypes of acute myocardial infarction according to Fourth Universal Definition 2018
Time frame: 12 months
Hospitalization due to unstable angina pectoris, bleeding, pacemaker and/or implantable/cardioverter defibrillator implantation, surgical or percutaneous heart valve treatment
Cardiovascular hospitalizations
Time frame: 3 years
All-cause mortality
All-cause mortality
Time frame: 3 years
All-cause mortality
Long-term registry based all-cause mortality at 10 years
Time frame: 10 years
Number and type of diagnostic tests performed
Cardiac CT, Exercise ECG, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography
Time frame: 12 months
Number of invasive coronary test not leading to coronary revascularization
number of invasive procedures
Time frame: 12 months
Number of coronary revascularization
Coronary bypass surgery and/or percutaneous coronary intervention
Time frame: 3 years
Cumulative iodinated contrast volume
Cardiac computed tomography, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, invasive optical coherence tomography
Time frame: 12 months
Cumulative radiation dose
Cardiac CT, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography
Time frame: 12 months
Major procedural complications occuring during procedures (invasive, non-invasive or coronary revascularization)
death, cardiac arrest, cardiac arrhytmia, acute myocardial infarction, stroke, bleeding, unplanned revascularization and any complication requiring and/or prolonging hospitalizaation at least 24 hours
Time frame: 12 months
Minor procedural complication specific to type of procedure (invasive, non-invasive or during coronary revascularization)
Minor procedural complications
Time frame: 12 months
Patients diagnosed with non-cardiac disease as likely explanation for symptoms
non-cardiac diseases causing chest pain
Time frame: 12 months
Seattle Angina Questionaire
Seattle Angina Questionaire pre-randomization, 3 months and 12 months after randomization
Time frame: 3 months and 12 months
Quality of life by EQ-5D-5L instrument
Quality of life estimated by EQ-5D-5L instrument pre-randomization, 3 months and 12 months after randomization
Time frame: 3 months and 12 months
Plan to share: Yes — Following publication of the main results of the trial, anonymized data will be made available to other researchers through the Zenodo open data repository.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Statistical Analysis Plan and study protocol a time of publication
Access criteria: Curated by principle investigator according to contemporary law
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 60 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2024 → Dec 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen University Hospital, Rigshospitalet